Brief: Invex Therapeutics Says Got UK Approval To Commence Phase Iii Trial
29/06/2022 01:58
June 29 (Reuters) - Invex Therapeutics Ltd IXC.AX :
* INVEX RECEIVES UK APPROVAL TO COMMENCE PHASE III TRIAL
* CLINICAL TRIAL FOR PRESENDIN DRUG FOR NEUROLOGICAL
CONDITIONS
RELATING TO RAISED INTRACRANIAL PRESSURE
Source text for Eikon: ID:nASX2WpH18
Further company coverage: IXC.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Invex Therapeutics
See all newsBrief: Invex Therapeutics Requests Trading Halt
Brief: Invex Therapeutics Says Narelle Warren Resigns As CFO
Brief: Invex Therapeutics' Negotiations Discontinued With Neurological Disease Therapeutics Development Co
Australia's Invex Therapeutics falls as agreement talks fade
Brief: Invex Therapeutics Seeks Trading Halt